University of California, San Diego

Simplilearn Joins Forces With University of California San Diego Division of Extended Studies to accelerate digital skills training

Retrieved on: 
Monday, September 25, 2023

BENGALURU, India, Sept. 25, 2023 /PRNewswire/ -- Simplilearn, the world's #1 online boot camp for digital skills training, today, announced a partnership with the University of California San Diego (UC San Diego) Division of Extended Studies to bring enhanced digital economy skills training to professionals and students in the United States, providing them the competitive advantage for well-paying, in-demand jobs in the state of California and beyond. 

Key Points: 
  • BENGALURU, India, Sept. 25, 2023 /PRNewswire/ -- Simplilearn , the world's #1 online boot camp for digital skills training, today, announced a partnership with the University of California San Diego (UC San Diego) Division of Extended Studies to bring enhanced digital economy skills training to professionals and students in the United States, providing them the competitive advantage for well-paying, in-demand jobs in the state of California and beyond.
  • The Division of Extended Studies is housed within UC San Diego, ranked #1 among the world's 'Golden Age' universities, and is certain to bring strong value to the learning and growth trajectory of professionals.
  • With a vision to empower learners with industry-oriented and marketable skills, this partnership will help nurture cohorts of high-quality professionals.
  • Dean Hugo Villar, UC San Diego Division of Extended Studies noted, "As technology advances, we can be certain that the demand for quality over quantity will take precedence.

Siebel Scholars Foundation Announces Class of 2024

Retrieved on: 
Tuesday, September 19, 2023

The Siebel Scholars Foundation today announced the recipients of the 2024 Siebel Scholars award.

Key Points: 
  • The Siebel Scholars Foundation today announced the recipients of the 2024 Siebel Scholars award.
  • The 83 distinguished students of the Class of 2024 join past Siebel Scholars classes to form an unmatched professional and personal network of more than 1,800 scholars, researchers, and entrepreneurs.
  • This year’s class is exceptional, and once again represents the best and brightest minds from around the globe who are advancing innovations in healthcare, artificial intelligence, financial services, and more,” said Thomas M. Siebel, Chairman of the Siebel Scholars Foundation.
  • On average, Siebel Scholars rank in the top five percent of their class, many within the top one percent.

Rady Children's Appoints Rush Chewning, MD, as Medical Director, Pediatric Interventional Radiology

Retrieved on: 
Wednesday, September 20, 2023

"As a top pediatric hospital, it has been a longstanding goal for us to establish a dedicated Pediatric Interventional Radiology program to effectively meet pediatric patients' needs and bring our existing radiology department to new heights."

Key Points: 
  • "As a top pediatric hospital, it has been a longstanding goal for us to establish a dedicated Pediatric Interventional Radiology program to effectively meet pediatric patients' needs and bring our existing radiology department to new heights."
  • He served as the junior representative to the Society for Pediatric Interventional Radiology (SPIR) board for two years from 2020 to 2022, supporting junior faculty and trainees in their careers and promoting awareness of pediatric Interventional Radiology to residents and medical students.
  • "Pediatric Interventional Radiology has so much to offer, including the potential to significantly improve patients' quality of life.
  • He completed his radiology residency at the University of Washington, where he also completed a Vascular and Interventional Radiology fellowship before a second fellowship in Pediatric Vascular and Interventional Radiology at Boston Children's Hospital.

Non-binary and transgender Californians suffered alarming levels of physical and sexual violence in the past year

Retrieved on: 
Tuesday, September 19, 2023

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- An annual survey of physical and sexual violence suffered by Californians documents for the first time the higher incidence of violence among non-binary and transgender people. One in 20 California adults has experienced physical violence (5%) in the past year, a decrease from 8% in 2022, according to The California Violence Experiences Study (CalVEX); but the reported rates for non-binary and transgender individuals were notably higher, 14% and 27%, respectively.

Key Points: 
  • WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- An annual survey of physical and sexual violence suffered by Californians documents for the first time the higher incidence of violence among non-binary and transgender people.
  • "These data have historically lacked information on non-binary and transgender individuals, so we have not had a clear picture of their experiences with violence until now."
  • Past year sexual harassment and assault reported by non-binary and transgender adults was egregiously higher, at 56% and 40%, respectively.
  • Overall, more than half of all adults in California reported physical or sexual partner violence (54%) against them in their lifetime.

CureScience™ Institute Fall-Spring Scholars Bioinformatics and Machine Learning Program

Retrieved on: 
Tuesday, September 19, 2023

The Fall-Spring Scholars Bioinformatics and Machine Learning Program invites students with a strong interest in science to fill out the online application on the CureScience™ Institute website.

Key Points: 
  • The Fall-Spring Scholars Bioinformatics and Machine Learning Program invites students with a strong interest in science to fill out the online application on the CureScience™ Institute website.
  • Students will have the opportunity to interact with CureScience scientists to conduct original, innovative research projects in areas such as: cancer biology, drug design, computational biology, infectious disease, machine learning, artificial intelligence, and more.
  • He is a world-known expert in structural biology, molecular modeling, bioinformatics, and using AI for drug design and treatment.
  • She has authored over 50 scientific papers, three books and eight book chapters, and 13 patents.

Former U.S. Navy Surgeon General Bruce Gillingham Joins Amplifire as a Strategic Advisor

Retrieved on: 
Thursday, September 14, 2023

As the former 39th Surgeon General of the United States Navy, Gillingham recently retired from 40 years of active-duty service.

Key Points: 
  • As the former 39th Surgeon General of the United States Navy, Gillingham recently retired from 40 years of active-duty service.
  • During his tenure, he led approximately 44,000 Navy medical personnel through the U.S. Navy Bureau of Medicine and Surgery’s (BUMED) most comprehensive transformation since World War II.
  • “Bruce Gillingham’s integrity and reputation for establishing elite patient care in adverse environments is an invaluable resource to Amplifire in healthcare and beyond.
  • “It is a true honor to collaborate with Dr. Gillingham in our shared mission.”
    “I’m thrilled to join the Amplifire team,” Bruce Gillingham expressed.

Semiconductor Research Corporation Recognizes Innovation and Excellence at their 25th TECHCON Networking Event

Retrieved on: 
Tuesday, September 12, 2023

Every year, Semiconductor Research Corporation honors excellence across the semiconductor research community with awards for industry professionals and university researchers.

Key Points: 
  • Every year, Semiconductor Research Corporation honors excellence across the semiconductor research community with awards for industry professionals and university researchers.
  • The Technical Excellence Award recognizes research of exceptional value to SRC members by significantly enhancing the productivity and competitiveness of the semiconductor industry.
  • The SRC Innovation Award recognizes patents and IP arising from SRC research that represent inventive approaches that have made a significant impact on the semiconductor industry.
  • Now in its 25th year, TECHCON is a unique event in the industry because it facilitates direct interaction between semiconductor industry professionals and SRC Research Scholars.

Shook Expands Auto Acumen in California with New Partner

Retrieved on: 
Tuesday, September 12, 2023

SAN FRANCISCO, Sept. 12, 2023 /PRNewswire/ -- Shook, Hardy & Bacon welcomes Partner Amy Kuo Alexander to advise the firm's automotive and manufacturing clients. Alexander hails from an AmLaw 30 firm and brings nearly 20 years of litigation experience in the automotive and construction sectors, among other areas. She will join Shook's General Liability Litigation Practice Group.

Key Points: 
  • SAN FRANCISCO, Sept. 12, 2023 /PRNewswire/ -- Shook, Hardy & Bacon welcomes Partner Amy Kuo Alexander to advise the firm's automotive and manufacturing clients.
  • One of our goals is to continue to expand our California presence to best serve clients with collaborative, innovative and creative solutions.
  • She earned her law degree from Loyola School of Law and her undergraduate degree in political science from the University of California, San Diego.
  • She is admitted to practice in the Northern, Eastern, Central and Southern Districts of California U.S. District Courts.

Esteemed Ophthalmologist, Dr. Nicole J. Topilow, Joins OCLI Vision's Expert Team

Retrieved on: 
Tuesday, September 12, 2023

GARDEN CITY, N.Y., Sept. 12, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to announce the addition of Dr. Nicole J. Topilow, MD, to their distinguished team of eye care specialists. Dr. Topilow is a highly skilled ophthalmologist with a specialization in ophthalmic plastic and reconstructive surgery. Her expertise and dedication to patient care make her a valuable asset to OCLI Vision, and she is set to commence her practice on September 18th, 2023.

Key Points: 
  • OCLI Vision proudly welcomes Dr. Nicole J. Topilow, a skilled ophthalmologist specializing in ophthalmic plastic and reconstructive surgery.
  • Dr. Topilow will be practicing across multiple OCLI Vision locations starting September 18th, 2023, offering her expertise to patients.
  • GARDEN CITY, N.Y., Sept. 12, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to announce the addition of Dr. Nicole J. Topilow, MD, to their distinguished team of eye care specialists.
  • "I couldn't be more excited to join OCLI Vision and support its mission to provide exceptional eye care to our community.

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Retrieved on: 
Wednesday, September 6, 2023

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.

Key Points: 
  • Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the clinical development opportunity for NXP800 in ovarian cancer, and specifically in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, a patient population that is currently being enrolled into an ongoing Phase 1b clinical trial in which the safety and preliminary efficacy of NXP800 is being investigated, and Gordon Mills, MD, PhD (Knight Cancer Institute, Oregon Health & Science University) who will discuss the clinical development opportunities for NXP900 as the Phase 1a dose escalation study is about to commence.
  • A live question and answer session will follow the formal presentations.